上海奥浦迈生物科技股份有限公司2025 年半年度报告摘要 公司代码：688293 公司简称：奥浦迈 上海奥浦迈生物科技股份有限公司 二〇二五年八月 上海奥浦迈生物科技股份有限公司2025 年半年度报告摘要 其中，为进一步回报广大股东，若公司 2025 年上半年盈利且满足现金分红条件，拟于 2025 年半 年度报告披露时增加一次中期分红，预计 2025 年中期现金分红金额不低于 2,500 万元。同时股东 大会授权董事会在符合利润分配的条件下制定具体的 2025 年度中期利润分配方案。 结合 2025 年半年度公司实际经营情况及财务状况，公司拟以权益分派实施股权登记日的股份 总数为基数，向全体股东每 10 股派发现金红利人民币 2.30 元（含税）。截至 2025 年 6 月 30 日， 公司总股本为 113,548,754 股，预计合计分配现金红利 26,116,213.42 元（含税），占公司 2025 年 半年度合并报表归属于上市公司股东净利润的 69.56%，占公司累计未分配利润的 23.80%。 □适用 √不适用 上海奥浦迈生物科技股份有限公司2025 年半年度报告摘要 第一节 重要提示 规划，投资者 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-062 上海奥浦迈生物科技股份有限公司 关于公司 2025 年中期利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 司2025年中期利润分配预案的议案》，监事会认为，公司本次2025年度中期利润 分配预案，充分考虑了公司日常运营及长远发展，结合了公司盈利情况、现金流 状态和资金需求等综合因素，同时合理考虑了股东回报，不存在损害中小股东利 益的情形，符合公司目前的生产经营情况，有利于公司持续、健康、长远发展。 监事会同意公司2025年中期利润分配预案。 关于公司2025年中期利润分配预案具体内容如下： 现金红利26,116,213.42元（含税），占2025年半年度当期合并报表归属于上市公 司股东净利润的69.56%；占公司合并报表累计未分配利润的23.80%。 根据《上海奥浦迈生物科技股份有限公司2025年半年度报告》（未经审计）， 截至2025年6月30日，上海奥浦迈生物科技股份有限公司（以下简称"公司"或 "奥浦迈"）202 ...

《上海证券交易所科创板股票上市规 则》以及《公司章程》等相关规定。同意调整公司 2025 年度部分日常关联交易预计 额度，并将该议案提交公司第二届董事会第十一次会议审议。 表决结果：3 票同意、0 票反对、0 票弃权；获全体独立董事审议通过。 上述议案尚需提交公司董事会审议。 上海奥浦迈生物科技股份有限公司董事会 独立董事：陶化安、张元兴、李晓梅 上海奥浦迈生物科技股份有限公司 第二届董事会独立董事专门会议第四次会议决议 上海奥浦迈生物科技股份有限公司（以下简称"公司"）第二届董事会独立董事 专门会议第四次会议于 2025 年 8 月 21 日通过线上通讯会议的方式召开。本次会议 应到独立董事 3 人，实到独立董事 3 人。本次会议的召集、召开程序符合相关法律、 行政法规、部门规章、规范性文件以及《上海奥浦迈生物科技股份有限公司独立董 事工作制度》的规定。 经与会独立董事审议表决，形成的会议决议如下： 一、审议通过了《关于调整 2025 年度部分日常关联交易预计额度的议案》 基于公司 2025 年生产经营实际需要，结合 2025 年上半年业务推进的实际情况， 同时基于对 2025 年下半年公司业务的合理预计， ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-060 上海奥浦迈生物科技股份有限公司 第二届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）第二 届董事会第十一次会议于2025年8月21日通过现场表决与通讯相结合的方式召开。 本次会议通知及相关资料已于2025年8月11日送达全体董事。本次会议由董事长 肖志华先生召集并主持，会议应出席董事7名，实际出席董事7名，本次会议的召 集、召开方式符合相关法律、行政法规、部门规章、规范性文件和《公司章程》 的规定，会议决议合法有效。 二、董事会会议审议情况 表决结果：7票同意、0票反对、0票弃权；获全体董事一致通过。 具体内容详见公司于同日刊载于上海证券交易所网站（www.sse.com.cn）的 《上海奥浦迈生物科技股份有限公司2025年半年度报告》及《上海奥浦迈生物科 技股份有限公司2025年半年度报告摘要》。 上述议案在提交董事会审议前已经审计委员会 ...

上海奥浦迈生物科技股份有限公司 第二届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688293 证券简称：奥浦迈 公告编号：2025-061 一、监事会会议召开情况 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）第二 届监事会第十次会议于2025年8月21日通过现场表决与通讯相结合的方式召开。 本次会议通知及相关资料已于2025年8月11日送达全体监事。本次会议由监事会 主席梁欠欠女士召集并主持，会议应出席监事3名，实际出席监事3名，本次会议 的召集、召开方式符合相关法律、行政法规、部门规章、规范性文件和《公司章 程》的规定，会议决议合法有效。 专项报告>的议案》 监事会认为：公司2025年半年度募集资金存放与实际使用情况符合《上海证 券交易所科创板股票上市规则》《上市公司募集资金监管规则》《上海奥浦迈生 物科技股份有限公司募集资金管理办法》等相关法律法规和公司制度的规定，公 司募集资金使用专户存储和专项使用，并及时履行了相关信息披露义务，募集资 金的使用审议程序合法 ...

品说明书（产品代码：NSH07654） 招商银行智汇系列看涨两层区间 7 天结构性存款产品 说明书（产品代码：FSH07881） 杭州银行"添利宝"结构性存款（挂钩汇率 B 款）协 议 杭州银行"添利宝"结构性存款（挂钩汇率 B 款）协 议 杭州银行大额存单 1,000.00 2025/3/24 2026/2/14 3.100 尚未到期 尚未到期 杭州银行"添利宝"结构性存款（挂钩汇率 B 款）协 1,600.00 2025/1/17 2025/7/27 2.300 尚未到期 尚未到期 议 招商银行定期存款 15,000.00 2025/1/24 2025/7/24 1.500 尚未到期 尚未到期 杭州银行"添利宝"结构性存款（挂钩汇率 B 款）协 议 招商银行点金系列看涨两层区间 91 天结构性存款产 品说明书（产品代码：NSH07999） 招商银行点金系列看涨两层区间 91 天结构性存款产 品说明书（产品代码：NSH08050） 杭州银行"添利宝"结构性存款（挂钩汇率 B 款）协 议（TLBB202509961） 杭州银行"添利宝"结构性存款（挂钩汇率 B 款）协 议（TLBB202509840） 杭州银 ...

Group 1 - The company will hold a half-year performance briefing on September 3, 2025, from 13:00 to 14:00 [1][2] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][3] - Key personnel attending the briefing include the Chairman, General Manager, CFO, independent directors, and the Secretary of the Board [2] Group 2 - Investors can submit questions for the briefing from August 27, 2025, to September 2, 2025, before 16:00 [3] - The company encourages participation through the Shanghai Stock Exchange Roadshow Center website [3] - After the briefing, investors can access the main content and details of the event on the same website [3]

Core Viewpoint - The company is committed to enhancing its core business and competitiveness through increased R&D investment and operational efficiency, while also focusing on investor returns and sustainable growth [1][5][6] Group 1: Business Focus and R&D Investment - The company specializes in cell culture products and services, aiming to provide comprehensive solutions for the biopharmaceutical industry [1] - R&D investment has consistently exceeded 10% of annual revenue, with a focus on developing proprietary technologies and expanding product lines [11][10] - The company has developed multiple new cell culture media products, enhancing its competitive edge in therapeutic protein production [12][13] Group 2: Financial Performance and Market Expansion - The sales revenue from cell culture products increased by 25.49% year-on-year, driven by the steady progress of client pipelines and rapid overseas expansion [2] - The company served over 700 domestic and international biopharmaceutical enterprises and research institutions, solidifying its market position [2][10] - The CDMO service business also showed positive growth, with a revenue increase of 13.24% compared to the previous year [2] Group 3: Investor Relations and Return Mechanisms - The company maintains a stable cash dividend policy, distributing a total of 22,709,750.80 yuan in cash dividends for the 2025 mid-year [5][6] - A share repurchase plan was completed, with a total transaction amount of 50,998,163.75 yuan, aimed at enhancing long-term investment value [7][8] - The company plans to implement a mid-year profit distribution of 2.30 yuan per share, amounting to 26,116,213.42 yuan, which represents 69.56% of the net profit for the first half of 2025 [6] Group 4: Internal Management and Quality Control - The company has successfully passed ISO9001:2015 quality management system audits, demonstrating its commitment to high-quality standards [16] - Continuous improvement in internal control systems and governance structures is prioritized to enhance operational efficiency and risk management [19][20] - The company emphasizes talent development, with over 70% of R&D personnel holding master's or doctoral degrees, fostering a strong innovation culture [17][18] Group 5: Future Outlook and Strategic Initiatives - The company is actively pursuing a major asset restructuring to enhance operational quality and risk resilience [17][18] - Plans to explore various share repurchase methods to strengthen capital structure and enhance investor value are in place [8] - The company aims to expand its international market presence while continuously optimizing product offerings and service quality [15][16]

Summary of Key Points Core Viewpoint - The company, Shanghai Aopumai Biotechnology Co., Ltd., plans to utilize part of its idle raised funds for cash management, with a maximum investment amount of RMB 700 million, ensuring high safety and liquidity in the investment products chosen [1][2][8]. Investment Overview - **Investment Purpose**: The aim is to maximize shareholder value by improving the efficiency of fund usage while ensuring that the use of raised funds is not affected and risks are effectively controlled [2][6]. - **Investment Amount and Duration**: The company intends to use up to RMB 700 million for cash management, with the funds being able to roll over within a 12-month period [2][5]. - **Source of Funds**: The funds are sourced from the proceeds of the company's initial public offering, which raised a total of approximately RMB 1.64 billion after deducting issuance costs [2][5]. Investment Methodology - The company will invest in high-safety, liquid financial products such as agreement deposits, structured deposits, time deposits, notice deposits, large certificates of deposit, and income certificates [1][5][6]. - The cash management products will not be used for pledging or for investment purposes in securities [5][6]. Approval Process - The board of directors and the supervisory board approved the cash management proposal during meetings held on August 21, 2025, with a validity period of 12 months from the date of approval [2][6][8]. - The management team has been authorized to make investment decisions and sign relevant contracts, with the finance department responsible for implementation [1][6]. Opinions from Supervisory Board and Sponsor - The supervisory board supports the cash management initiative, stating it will not affect the use of raised funds or harm the interests of the company and its shareholders [7][8]. - The sponsor, Guotai Junan Securities, has confirmed that the cash management plan complies with relevant regulations and will enhance fund usage efficiency without altering the intended use of raised funds [8].

Core Viewpoint - The company has approved the formulation and revision of certain governance systems to enhance operational standards and protect shareholder rights [1][2]. Group 1: Governance System Revisions - The board of directors convened on August 21, 2025, to review and approve the proposal for governance system revisions [1]. - The revisions are in accordance with various laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1]. - The specific governance systems being established and revised include the "Market Value Management System" and the "Public Opinion Management System" [1]. Group 2: Market Value Management System - The "Market Value Management System" consists of five chapters and seventeen articles, covering basic principles, management structure, main methods, monitoring mechanisms, and emergency measures [2]. - The aim of this system is to enhance the company's market value management practices and improve investor returns [1][2]. Group 3: Public Opinion Management System - The "Public Opinion Management System" includes four chapters and sixteen articles, focusing on the organizational structure and responsibilities for managing public opinion, as well as principles and measures for handling various types of public opinion information [2]. - This system is designed to strengthen the company's ability to respond to public sentiment and establish a rapid response and emergency handling mechanism [1][2].